Dasatinib (Sprycel®) for the treatment of Lymphoid blast CML and PH+ ALL
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000451
English
Authors' recommendations:
Dasatinib (Sprycel®) is not recommended for use within NHS Wales for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myeloid leukaemia (LB-CML) with resistance or intolerance to prior therapy.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=91894&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Philadelphia Chromosome
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Pyrimidines
- Thiazoles
- Leukemia, Lymphoid
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.